Rebirth of the God-level Xueba

It is not only Grace who is following the scientific research progress of Huarui Laboratory, but also Zeleca, as well as pharmaceutical companies from Japan and Norway.

After discovering the rapid decline in the number of candidate compounds in the Huarui laboratory, several companies inquired about the situation.

The 8 candidate compounds are considered to be an important node. If the rapid decline is due to technical reasons such as safety, it means that this compound may not pass animal experiments, but if it is the opposite, it means that this compound has a lot of room for selection.

Ample choice space means that the cost may be greatly reduced.

Yang Rui made more than 30 kinds of compounds in one breath, and the synthetic routes he adopted were naturally strange. Some routes were thought to be normal, which was simply unimaginable.

Nevertheless, most of the more than 30 compounds use some expensive raw materials or catalysts.

This is not to say that expensive raw materials or catalysts cannot be used in drugs. The key to the problem is profit.

These companies pay attention to the catalyst formulation of coenzyme q10 for profit, and pay attention to deferiprone for profit.

Moreover, compared with the catalyst formulation of coenzyme q10, the grade of deferiprone is much higher.

A new drug, for a super-large company like Pfizer, is also a few core projects each year, and for an ordinary medium and large pharmaceutical company, it often represents a fraction of the company's assets.

In short, if a pharmaceutical company can produce a new drug, it will rank among the world's pharmaceutical companies.

Don't look at the tens of thousands or even more pharmaceutical companies in the world. Among them, 99 are generic drug companies.

Generic drug companies are not necessarily weak, but original drug companies are definitely strong. Whether it is the strength of the strength, the strength of the laboratory, or the strength of the spirit, it is all strong, because the strong strength, laboratory and spirit brought by a new drug may be transformed into money in the future.

Dozens of new drugs appear worldwide every year. Half and half of half and more than half of half of half. All belong to multinational pharmaceutical companies.

The rest belong to small and medium-sized pharmaceutical companies, and there may not be one in a year.

This is a risky business.

However, there are still people who have been thrown into it one after another.

Zelikang is a multinational pharmaceutical company with annual sales exceeding tens of billions of dollars. However, the number of new drugs they can increase each year is also very limited, usually hovering around three.

Deferiprone may not be a blockbuster, but who knows

Many drugs have only developed new indications after they are on the market. Then it leapt to become a billion-ten billion aerial bomb in marketing.

Therefore, people who originally stared at the coenzyme q10 catalyst also inevitably stared at deferiprone, which has been very smooth in animal experiments.

But Yang Rui did not agree to visits by companies such as Zelecom, let alone the visits of Japanese and Norwegian companies.

He didn't even let Grace know his detailed experimental process. Only the briefing came out of the small compartment and appeared in front of others in the morning report.

So, in the next two days, Yang Rui once again removed a compound, and then ended his independent work in the laboratory.

The remaining 7 compounds are not too risky. In fact, they are all possible as finished drugs for deferiprone. Several of them are appearing as generic drugs, and naturally there is no major safety issue.

Yang Rui only needs to proceed step by step and let them complete the animal experiment.

And the closer it gets to completion, the more curious companies such as Zelecom are.

At this stage, they are really just curious.

However, this kind of curiosity also makes them feel unbearable.

On the third day when Yang Rui selected the last seven compounds, Frankie brought a group of people directly to Peking University.

The so-called monk can't run to the temple if he can run, Yang Rui can't run away when he finds Peking University.

Not only can't you run away, but you can't keep a low profile at all.

A group of foreigners have arrived at school, and everyone must be aware of it.

When Yang Rui received the call and came outside to pick up people, Dean Liu also ran out.

"Oh, so many international friends come to visit our school, Yang Rui, why don't you tell me what is it for this time?" Dean Liu said as if complaining, his eyes bright like monkeys.

"For the research on deferiprone in Huarui Lab." Yang Rui explained in one sentence.

Dean Liu naturally knew about this, and he said, "Oh," he said, "It's all for this medicine. Didn't you say you don't make money?"

"It won't make a profit in the short term, but it may not be the case in the long run." Yang Rui went on to say: "In any case, it is an original drug, and there are many patents for an original drug. There are many benefits."

"It's like saying that I smelled a fishy shark again" Dean Liu nodded in understanding.

Yang Rui smiled: "It's not that serious, it's the animal experiment stage. They can't make money even if they take it."

There are tens of millions of drugs that pass animal experiments every year, and only a few are valuable.

"What are you here for?" Dean Liu's attitude changed quickly.

"It still smells fishy, ​​but I didn't see the meat. I guess it won't be too aggressive."

Yang Rui turned around and took Dean Liu to entertain foreign company representatives from afar.

The director of the cafeteria also went there and asked along the way: "Should we open a private room, what shall we give them?"

"Just eat the documents." Yang Rui replied simply and neatly. When he arrived at the place, he really fed a bunch of documents to a group of people.

Arnold and the others were happy, and quickly looked through it. Grace was the first to grab it and said, "It's too thin."

"After you go back to the lab, I will give you a thicker version." Yang Rui smiled and soothed, saying that he came to work for nothing, and he should be given some privileges.

Grace seemed quite satisfied, but the change in her expression was very weak, just looking at the information.

Arnold muttered a word beside him, comparing the completion of various aspects of the animal experiment item by item.

Clinical candidate compounds have some iconic characteristics. The more these characteristics have, the more necessary it is to conduct clinical trials.

Zeneca is a multinational company that often does mergers and acquisitions. It has its own method. By scoring these characteristics, he can judge the approximate value of a compound.

Frankie helped Arnold quietly calculate ~www.NovelMTL.com~ and said: "It is effective on animal models, no genetic toxicity, no acute or chronic toxicity, and the basic 15 points can be obtained."

"The target point of action has been clinically verified. Iron chelator is very simple, count 3 points. There is a competitive advantage, but can it be stronger than deferoxamine"

"Calculate 2 points, a total of five points."

"That's 20 points. In terms of raw materials and costs, these compounds are different. I can see that they can basically get a five-point. 25 points." Arnold took a breath.

Zeleca’s calculation formulas are simple and complex, but they have never been given a 60-point standard. With their current oral calculation formulas, those that can reach 30 points are extremely high scores, and companies generally come in contact with them and try to acquire them. .

Frankie looked down at the file and said: "Seven backup compounds, at least 10 points should be given."

"Well, their animal experiments have not yet been completed. I don't think we can forget about the backup compound item. Who knows that there will be a few that will pass." Arnold did not want to give a high score of 35 points.

Frankie said indifferently: "Because it is a rare disease drug, there is a 7-year drug monopoly period, do you want extra points for this?"

Arnold hesitated for a moment, and said: "Nevertheless, rare diseases mean low sales. If the monopoly is to make up for the lack of sales, it will count as 3 points."

Although it was only a private estimate, he was not embarrassed to be too unfair.

Frank said: "That's 28 points."

"Well" Arnold looked at the uncalculated items in the row below, a bit sore.